CureVac N.V. Files 6-K for Q1 2025
| Field | Detail |
|---|---|
| Company | Curevac N.V. |
| Form Type | 6-K |
| Filed Date | May 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, collaboration, biotech
Related Tickers: CVAC
TL;DR
CureVac's Q1 2025 6-K is out, showing ongoing GSK & CRISPR deals. No big numbers yet.
AI Summary
CureVac N.V. filed a 6-K report for the period ending March 31, 2025. The filing includes details on various collaborations and services, such as those with GlaxoSmithKline and CRISPR, and mentions goods or services transferred over time and at a point in time. Specific financial figures for these transactions are not detailed in this excerpt.
Why It Matters
This filing provides an update on CureVac's ongoing business activities and partnerships, which are crucial for its product development and revenue generation in the biopharmaceutical sector.
Risk Assessment
Risk Level: low — This is a routine 6-K filing providing operational updates, not a material event like an acquisition or significant financial distress.
Key Players & Entities
- CureVac N.V. (company) — Filer of the 6-K report
- GlaxoSmithKline (company) — Collaborator mentioned in the filing
- CRISPR (company) — Collaborator mentioned in the filing
FAQ
What is the reporting period for this 6-K filing?
The Conformed Period of Report is 20250331, indicating the filing covers the period ending March 31, 2025.
What is CureVac N.V.'s standard industrial classification?
CureVac N.V.'s Standard Industrial Classification is Pharmaceutical Preparations [2834].
When was CureVac N.V. formerly known as CureVac B.V. and when did the name change occur?
CureVac N.V. was formerly known as CureVac B.V., and the date of the name change was 20200410.
What types of goods or services are mentioned as being transferred in the filing?
The filing mentions 'GoodsOrServicesTransferredOverTimeMember' and 'GoodsOrServicesTransferredAtPointInTimeMember'.
Are there specific financial amounts mentioned for the collaborations with GlaxoSmithKline or CRISPR in this excerpt?
No specific dollar amounts for the collaborations with GlaxoSmithKline or CRISPR are detailed in this excerpt of the filing.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 20, 2025 regarding CureVac N.V..